Monte Rosa Therapeutics (GLUE) vs Immatics N.V. (IMTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Monte Rosa Therapeutics (GLUE) has outperformed Immatics N.V. (IMTX) over the past year, gaining 37.8% versus a loss of 20.8%. Over five years, IMTX leads with a -46.2% price change compared with -52.0% for GLUE. Immatics N.V. is the larger company by market cap ($1.13 billion vs $880.4 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLUE | IMTX |
|---|---|---|
| Share price | $10.32 | $7.40 |
| Market cap | $880.43M | $1.13B |
| 1-day change | +1.47% | -0.67% |
| YTD return | -35.14% | -29.05% |
| 1-year return | +37.80% | -20.83% |
| 5-year return | -52.03% | -46.21% |
| EPS (TTM) | $-1.75 | $-1.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.77 | $12.41 |
| 52-week low | $7.65 | $7.02 |
| Distance from 52-week high | -59.95% | -40.37% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +171.32% | +138.24% |
| Average volume | 1.31M | 595.07K |
| Shares outstanding | 85.31M | 152.23M |
| Employees | 173 | 704 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLUE has outperformed IMTX by 58.6 percentage points over the past year.
About Monte Rosa Therapeutics
GLUE stock →Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 173 employees
About Immatics N.V.
IMTX stock →Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 704 employees
GLUE vs IMTX FAQ
Which is bigger, Monte Rosa Therapeutics or Immatics N.V.?
Immatics N.V. (IMTX) is larger, with a market capitalization of $1.13B compared with $880.43M for Monte Rosa Therapeutics (GLUE).
Which stock has performed better over the past year, GLUE or IMTX?
GLUE returned +37.80% over the past 12 months, compared with -20.83% for IMTX (price return, excluding dividends). Past performance does not predict future results.
Are Monte Rosa Therapeutics and Immatics N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.